С бронхиальной астмой в ходе иммунотерапии аутологичными активированными Т-клетками; Перспективы развития фундаментальных наук; Т. 4 : Биология и фундаментальная медицина

Detaylı Bibliyografya
Parent link:	Перспективы развития фундаментальных наук=Prospects of Fundamental Sciences Development: сборник научных трудов XV Международной конференции студентов, аспирантов и молодых ученых, г. Томск, 24-27 апреля 2018 г./ Национальный исследовательский Томский политехнический университет (ТПУ) ; под ред. И. А. Курзиной, Г. А. Вороновой.— , 2018 Т. 4 : Биология и фундаментальная медицина.— 2018.— [С. 15-17]
Yazar:	Блинова Е. А.
Müşterek Yazar:	Научно-исследовательский институт фундаментальной и клинической иммунологии
Diğer Yazarlar:	Макарова А. Е. (научный руководитель), Пашкина Е. А., Козлов В. А.
Özet:	Заглавие с экрана In this study we investigated quality of life and immune status of patients with bronchial asthma (BA) during immunotherapy with autologous activated T-cells. Activated T-cells was injected subcutaneously according to scheme after receiving informed consent from patients. In the end of therapy course, it was observed a decreasing of symptoms and disease influence on patients' life. Patients with atopic BA demonstrated significant decline of IgE level after 2 and 7 months after beginning of the therapy, and there was no changes in IgE level in non-atopic patients. Immunotherapy with T-cells corrected the number of B-cells and phagocutic activity of granulocytes and monocytes that differed from the normative values.
Dil:	Rusça
Baskı/Yayın Bilgisi:	2018
Konular:	электронный ресурс бронхиальная астма иммунотерапия иммунная система терапия биологические препараты
Online Erişim:	http://earchive.tpu.ru/handle/11683/50866
Materyal Türü:	Elektronik Kitap Bölümü
KOHA link:	https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=627634

Diğer Bilgiler
Özet:	Заглавие с экрана In this study we investigated quality of life and immune status of patients with bronchial asthma (BA) during immunotherapy with autologous activated T-cells. Activated T-cells was injected subcutaneously according to scheme after receiving informed consent from patients. In the end of therapy course, it was observed a decreasing of symptoms and disease influence on patients' life. Patients with atopic BA demonstrated significant decline of IgE level after 2 and 7 months after beginning of the therapy, and there was no changes in IgE level in non-atopic patients. Immunotherapy with T-cells corrected the number of B-cells and phagocutic activity of granulocytes and monocytes that differed from the normative values.

Benzer Materyaller